Michael R. Lucey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Michael R. Lucey has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
J R Lake
Committee for Liver and Intra‐abdominal Organs, American Society of Transplant Physicians, USA
2 shared publicationsK A Brown
Committee for Liver and Intra‐abdominal Organs, American Society of Transplant Physicians, USA
2 shared publicationsB A Crider
1 shared publicationD P Normolle
1 shared publicationD S Mackie
1 shared publicationE B Keeffe
Committee for Liver and Intra‐abdominal Organs, American Society of Transplant Physicians, USA
1 shared publication
Latest Publications
- 1 February 2001
- Published by Wolters Kluwer Health in Hepatology
- Vol. 33 (2) , 473-475
Predicting the Prognosis of Chronic Liver Disease: An Evolution From Child to Meld
- 1 February 2001
- Published by Wolters Kluwer Health in Hepatology
- Vol. 33 (2) , 473-475
Predicting the Prognosis of Chronic Liver Disease: An Evolution From Child to Meld
- 1 October 1998
- Published by Wolters Kluwer Health in Transplantation
- Vol. 66 (7) , 956-962
MINIMAL CRITERIA FOR PLACEMENT OF ADULTS ON THE LIVER TRANSPLANT WAITING LIST
- 1 October 1998
- Published by Wolters Kluwer Health in Transplantation
- Vol. 66 (7) , 956-962
MINIMAL CRITERIA FOR PLACEMENT OF ADULTS ON THE LIVER TRANSPLANT WAITING LIST
- 1 November 1997
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 3 (6) , 628-637
Minimal criteria for placement of adults on the liver transplant waiting list: A report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases
- 1 November 1997
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 3 (6) , 628-637
Minimal criteria for placement of adults on the liver transplant waiting list: A report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases
- 1 May 1997
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 3 (3) , 347-350
Liver transplantation for alcoholic liver disease: executive statement and recommendations
- 1 May 1997
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 3 (3) , 347-350
Liver transplantation for alcoholic liver disease: executive statement and recommendations
- 1 February 1995
- Vol. 21 (2) , 366-72
A double-blind, randomized, placebo-controlled trial of prostaglandin E1 in liver transplantation.
A double-blind placebo-controlled trial of intravenous prostaglandin PGE1 (40 micrograms/h) was conducted in adult orthotopic liver transplant recipients. Infusion was started intraoperatively and continued for up to 21 days. Patients were followed up for 180 days postoperatively. Among 172 patients eligible for treatment in the study, 160 could be evaluated (78 PGE1; 82 placebo). Patient and graft survival were similar (PGE1: 16 deaths, 9 retransplantations [7 survivors]; controls: 15 deaths, 6 retransplantations [3 survivors]). In patients with surviving grafts, however, PGE1 administration resulted in a 23% shorter mean duration of hospitalization following transplantation (PGE1: 24.4 days; controls: 31.8 days; P = .02) and a 40% shorter length of time postoperatively in the intensive care unit (PGE1: 8.2 days; controls 13.7 days; P = .05). Reduced needs for renal support (P = .03) or surgical intervention other than retransplantation (P = .02) were also noted with PGE1 use. Further, PGE1 administration resulted in a trend toward improved survival rates in patients with mild renal impairment (preoperative serum creatinine 1.5 mg percent or greater; P = .08). Neither the incidence of acute cellular rejection nor of primary nonfunction was significantly different in the two groups. Phlebitis was the only complication that was more common during PGE1 administration, (PGE1: 9; controls: 4). These results suggest that PGE1 use in hepatic allograft recipients reduces morbidity and may result in sizable cost reductions.
- 1 February 1995
- Vol. 21 (2) , 366-72
A double-blind, randomized, placebo-controlled trial of prostaglandin E1 in liver transplantation.
A double-blind placebo-controlled trial of intravenous prostaglandin PGE1 (40 micrograms/h) was conducted in adult orthotopic liver transplant recipients. Infusion was started intraoperatively and continued for up to 21 days. Patients were followed up for 180 days postoperatively. Among 172 patients eligible for treatment in the study, 160 could be evaluated (78 PGE1; 82 placebo). Patient and graft survival were similar (PGE1: 16 deaths, 9 retransplantations [7 survivors]; controls: 15 deaths, 6 retransplantations [3 survivors]). In patients with surviving grafts, however, PGE1 administration resulted in a 23% shorter mean duration of hospitalization following transplantation (PGE1: 24.4 days; controls: 31.8 days; P = .02) and a 40% shorter length of time postoperatively in the intensive care unit (PGE1: 8.2 days; controls 13.7 days; P = .05). Reduced needs for renal support (P = .03) or surgical intervention other than retransplantation (P = .02) were also noted with PGE1 use. Further, PGE1 administration resulted in a trend toward improved survival rates in patients with mild renal impairment (preoperative serum creatinine 1.5 mg percent or greater; P = .08). Neither the incidence of acute cellular rejection nor of primary nonfunction was significantly different in the two groups. Phlebitis was the only complication that was more common during PGE1 administration, (PGE1: 9; controls: 4). These results suggest that PGE1 use in hepatic allograft recipients reduces morbidity and may result in sizable cost reductions.